News about Biotechnology

Dyadic International Partners with Intralink to Strengthen Biotech Footprint in Japan and South Korea

Dyadic International, Inc. (operating as Dyadic Applied BioSolutions), a US-based biotechnology innovator, has appointed international business development consultancy Intralink to expand its commercial presence in Japan and South Korea — two of Asia’s fastest-growing and most advanced biopharmaceutical markets.

Biotechnology | 10/11/2025 | By Darshana |  252

Bharat Biotech Launches Nucelion, a New CRDMO Focused on Cell and Gene Therapies

The new entity, based in Genome Valley, Hyderabad, is designed to partner with global life-science innovators to deliver end-to-end solutions for complex biologic medicines.

Biotechnology | 03/11/2025 | By Darshana |  488

FDA Grants Tentative Approval to Amneal Pharmaceuticals' Generic Version of QVAR Inhalation Aerosol

Beclomethasone dipropionate HFA inhalation aerosol is a corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy in patients aged five years and older. It is not indicated for the relief of acute bronchospasm.

Biotechnology | 31/10/2025 | By Darshana |  268

Medinet Japan partners with India's Stempeutics for Stempeucel cell therapy to treat CLTI

Medinet Co., Ltd, a Tokyo-listed regenerative medicine and CDMO company, has signed an option licence agreement with India-based Stempeutics Research for the development and commercialisation of its Stempeucel therapy in Japan, targeting Chronic Limb Threatening Ischaemia (CLTI).

Biotechnology | 29/10/2025 | By Darshana |  332

DPIIT and Thermo Fisher Scientific Sign MoU to Strengthen India's Biotech Startup Ecosystem

The partnership between DPIIT and Thermo Fisher Scientific to support 500+ biotech startups through advisory, mentorship and nationwide challenge.

Biotechnology | 04/10/2025 | By Dineshwori |  334

Alkem Launches Pertuzumab Biosimilar Pertuza in India for HER2-Positive Breast Cancer

Alkem Laboratories has introduced Pertuza, a biosimilar of pertuzumab, in India for the treatment of HER2-positive breast cancer. The drug is supplied as a 420 mg/14 mL injection and is developed and manufactured domestically.

Biotechnology | 23/09/2025 | By Darshana |  407

Abzena Enhances AbZelectPRO Cell Line Offering with New GS Knockout Platforms

Named AbZelectPRO-KO and AbZelectPRO-KO+, the new GS knockout platforms are available as a stand-alone CLD offering, or as a fully integrated GMP programme, with fully transparent pricing to IND with no royalty fees. This flexible offering will enable customers to select a CLD strategy that aligns with their project-specific goals, timeline and budget.

Biotechnology | 15/09/2025 | By Dineshwori |  243

Cellectar Biosciences Partners with ITM to Secure Actinium-225 Supply for Cancer Drug Development

Cellectar Biosciences, Inc., a late-stage clinical biopharmaceutical company focused on cancer drug discovery and development, has entered into a supply agreement with ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech firm, for Actinium-225 (Ac-225).

Biotechnology | 15/09/2025 | By Darshana |  256

RION Forms INTENT Biologics to Develop Clinical Exosome-Based Therapies

With the launch of INTENT Biologics, RION targets global impact in inflammation care; Suneet Varma named CEO to lead the charge.

Biotechnology | 11/09/2025 | By Dineshwori |  502

Polpharma Biologics Partners with MS Pharma to Commercialize Biosimilars in MENA Region

Polpharma Biologics S.A., a biotechnology company specializing in the development and manufacturing of biosimilars, has entered into licensing agreements with MS Pharma, a leading biosimilar producer and distributor in the Middle East and North Africa (MENA) region.

Biotechnology | 03/09/2025 | By Darshana |  327